Opdualag Injection
NDC 0003-7125
Product Information
Opdualag (nivolumab and relatlimab-rmbw) is a BLA-approved product labeled by E.r. Squibb & Sons, L.l.c.. This medication is typically used as a lymphocyte activation gene-3 antagonists [moa]. It is supplied as a injection for intravenous administration. This product entry covers the primary NDC 0003-7125 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 0003-7125?
What are the uses of this product?
What are Active Ingredients of this product?
- NIVOLUMAB 12 mg/mL - A genetically engineered, fully humanized immunoglobulin G4 monoclonal antibody that binds to the PD-1 RECEPTOR, activating an immune response to tumor cells. It is used as monotherapy or in combination with IPILIMUMAB for the treatment of advanced malignant MELANOMA. It is also used in the treatment of advanced or recurring NON-SMALL CELL LUNG CANCER; RENAL CELL CARCINOMA; and HODGKIN'S LYMPHOMA.
- RELATLIMAB 4 mg/mL
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- NIVOLUMAB (UNII: 31YO63LBSN)
- NIVOLUMAB (UNII: 31YO63LBSN) (Active Moiety)
- RELATLIMAB (UNII: AF75XOF6W3)
- RELATLIMAB (UNII: AF75XOF6W3) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- HISTIDINE (UNII: 4QD397987E)
- HISTIDINE MONOHYDROCHLORIDE MONOHYDRATE (UNII: X573657P6P)
- PENTETIC ACID (UNII: 7A314HQM0I)
- POLYSORBATE 80 (UNII: 6OZP39ZG8H)
- SUCROSE (UNII: C151H8M554)
- WATER (UNII: 059QF0KO0R)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 2596778 - nivolumab-relatlimab-rmbw 240 MG / 80 MG in 20 ML Injection
- RxCUI: 2596778 - 20 ML nivolumab-rmbw 12 MG/ML / relatlimab-rmbw 4 MG/ML Injection
- RxCUI: 2596778 - nivolumab-relatlimab-rmbw 240 MG / 80 MG per 20 ML Injection
- RxCUI: 2596784 - Opdualag 240 MG / 80 MG in 20 ML Injection
- RxCUI: 2596784 - 20 ML nivolumab-rmbw 12 MG/ML / relatlimab-rmbw 4 MG/ML Injection [Opdualag]
Which are the Pharmacologic Classes of this product?
- Lymphocyte Activation Gene-3 Antagonists - [MoA] (Mechanism of Action)
- Lymphocyte Activation Gene-3 Blocker - [EPC] (Established Pharmacologic Class)
- Programmed Death Receptor-1 Blocking Antibody - [EPC] (Established Pharmacologic Class)
- Programmed Death Receptor-1-directed Antibody Interactions - [MoA] (Mechanism of Action)
* Please review the full disclaimer at the bottom of this page.
Patient Education
Nivolumab and relatlimab-rmbw
Nivolumab and relatlimab is used to treat certain types of melanoma (a type of skin cancer) that has spread to other parts of the body or cannot be removed by surgery in adults and children 12 years of age or older who weigh at least 40 kg. Nivolumab and relatlimab are in a class of medications called monoclonal antibodies. They work by helping your immune system to slow or stop the growth of cancer cells.
[Learn More]
* Please review the full disclaimer at the bottom of this page.